When the Mylan pharmaceutical giant raised the price of EpiPens by nearly 500%, it created a major controversy. Heather Bresch, CEO of Mylan said that the controversy created by her company has ‘opened a window into a broken system.’
The head of the pharmaceutical giant Mylan is speaking out about the firestorm created by the nearly-500 percent increase in the price of EpiPens.
Mylan CEO Heather Bresch was called to testify before Congress last year about the huge price increase for the life-saving allergy medicine to $600. After the controversy, the company cut the list price of generic EpiPens to $300.
In an interview with “CBS This Morning” co-host Norah O’Donnell, Bresch said bigger change is needed to fix what she calls a broken healthcare system.
“You took it on the chin this summer. Before Congress and in the public,” O’Donnell said.
GET MORE STORIES LIKE THIS
IN YOUR INBOX!
Sign up for our daily email and get the stories everyone is talking about.
